Wegovy® (semaglutide 2.4mg) is a once-weekly, FDA-approved injectable medication for chronic weight management and, as of 2024, for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. At Midwest Mind & Body Healthcare in Papillion, we prescribe Wegovy to appropriate candidates and manage treatment carefully, in-person in Nebraska or by telehealth across 16 states.
Wegovy's active ingredient is semaglutide, a GLP-1 receptor agonist. It works by slowing gastric emptying, blunting appetite signals in the hypothalamus, and improving satiety after meals. Clinical trials (STEP program) showed adults with obesity lost an average of 15% of body weight over 68 weeks on semaglutide 2.4mg plus lifestyle support, and the SELECT trial demonstrated a 20% relative reduction in major adverse cardiovascular events in adults with established CVD and overweight or obesity. Wegovy is FDA-approved for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
Our founder, Kim Wohlwend, MSN, APRN, is a dual ANCC board-certified Family Nurse Practitioner and Psychiatric-Mental Health Nurse Practitioner. Obesity is rarely a single-organ problem: thyroid status, sleep architecture, insulin resistance, mood, medication side effects, and perimenopause all shape how weight accumulates and how it responds to GLP-1 therapy. Treating obesity well requires someone who reads a lab panel and a medication list, not an algorithm that ships vials. That distinction matters, and it is why we run a clinic-based prescribing model rather than an automated subscription service.
This page explains who qualifies for Wegovy, how our program works, transparent pricing, and the Important Safety Information every patient should read before starting. If you are also considering tirzepatide, see our Zepbound prescribing page.
Who Qualifies
FDA-approved candidates for Wegovy.
Wegovy is a prescription medication, not a cosmetic weight-loss product. FDA labeling defines clear eligibility criteria based on BMI and weight-related medical conditions. We confirm eligibility during your initial evaluation and, if you do not qualify, we tell you plainly and help you find an appropriate path.
BMI 30 or higher
Obesity as defined by BMI, with or without other weight-related medical conditions. This is the primary FDA-approved indication for chronic weight management with Wegovy.
BMI 27 or higher with a comorbidity
Overweight with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Also an FDA-approved indication.
Type 2 diabetes with weight goals
Patients with T2DM who also meet the BMI criterion and have weight management as a shared goal with their diabetes clinician. Semaglutide also improves glycemic control.
Established CVD with overweight or obesity
As of March 2024, Wegovy is FDA-approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) in adults with established cardiovascular disease and overweight or obesity.
Prior weight-loss attempts that haven't lasted
Adults who have made honest attempts at diet, exercise, and behavior change and have not achieved durable results. Obesity is a chronic, relapsing condition; prior non-response to lifestyle alone is not a moral failing.
Metabolic syndrome
The cluster of abdominal obesity, elevated triglycerides, low HDL, elevated blood pressure, and elevated fasting glucose. GLP-1 therapy often improves multiple components simultaneously.
Weight-driven obstructive sleep apnea
OSA that is worsened or driven by excess weight. Semaglutide 2.4mg has demonstrated meaningful improvement in apnea-hypopnea index for patients with obesity-related OSA in recent trials.
Weight-driven joint and mobility issues
Knee osteoarthritis, hip pain, or chronic back pain worsened by excess weight. Meaningful weight reduction improves function, reduces analgesic requirements, and can delay or avoid joint replacement.
How It Works
A real clinician, a real plan, and a real titration.
Initial evaluation with labs
A 30 to 45 minute visit covering weight history, medical and psychiatric history, current medications, prior weight-loss attempts, and lifestyle context. Baseline labs typically include CMP, fasting lipid panel, HbA1c, TSH, and a pregnancy test when indicated. We confirm FDA eligibility and review contraindications, including personal or family history of medullary thyroid carcinoma or MEN 2.
Individualized titration plan
Wegovy titrates slowly to minimize gastrointestinal side effects: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg, advancing every 4 weeks over at least 16 weeks. Some patients tolerate standard titration; others need longer at an intermediate dose. We write the plan around how you actually feel, not a rigid calendar.
Ongoing monitoring and refills
Brief check-ins every 4 to 8 weeks during titration, then every 3 months once you are stable. We track weight, blood pressure, side effects, and periodically recheck labs. Refill visits are $60 each and typically take 15 minutes. You keep refills coming only as long as it is clinically appropriate to continue.
Pricing & Cost
$60 visit + medication. That's it.
Initial Consult
- Eligibility review and lab interpretation
- Risk-benefit discussion
- Prescription sent electronically
- Prior authorization prepared when applicable
Refill Visit
- Weight and side-effect check
- Dose adjustment as needed
- New prescription sent to your pharmacy
- No subscription, no auto-charge
Medication is billed separately by your pharmacy. Our $60 fees cover the clinical work of prescribing and monitoring. The cost of Wegovy itself depends on your insurance and pharmacy.
Insurance coverage. Many commercial plans cover Wegovy for chronic weight management, usually with a prior authorization documenting BMI and weight-related conditions. We prepare prior authorizations as part of the initial visit at no additional fee. Medicare does not currently cover Wegovy for weight loss alone, but it may cover semaglutide for the cardiovascular risk-reduction indication in qualifying patients.
Cash price for Wegovy without insurance is approximately $1,000 per month at retail pharmacies. Novo Nordisk offers a savings program that can reduce cost for commercially insured patients. NovoCare Pharmacy also offers direct-to-patient cash pricing that is typically lower than retail. We help you understand which path is cheapest for your situation.
Compared to subscription telehealth. Many online clinics charge $200 to $400 per month as a bundled subscription. Our visit-based model keeps your total costs transparent: you pay us only for clinical work and buy the brand-name medication directly from a pharmacy using your best available coverage. Read more on our prescribing and safety terms page.
Important Safety Information
What every Wegovy patient should know.
This is an abbreviated summary of the Wegovy prescribing information. Review the full Medication Guide and Prescribing Information provided with the medication and discuss any concerns with your clinician before starting.
Boxed Warning · Risk of Thyroid C-Cell Tumors
Wegovy causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents. It is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of the rodent findings has not been determined.
Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to semaglutide or any product component
Common side effects
The most common adverse reactions (reported in at least 5% of patients) are gastrointestinal. Nausea occurs in approximately 44% of patients, along with vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia (in patients with T2DM), flatulence, gastroenteritis, and gastroesophageal reflux disease. Most GI side effects are mild to moderate in severity, occur during titration, and typically improve with time. Slow titration, smaller meals, adequate hydration, and avoiding high-fat foods all help.
Serious warnings and precautions
- Acute pancreatitis. Has been reported in patients treated with GLP-1 receptor agonists. Discontinue promptly if pancreatitis is suspected. Do not restart if confirmed.
- Acute gallbladder disease. Cholelithiasis and cholecystitis have occurred; substantial weight loss itself increases this risk. Evaluate new right-upper-quadrant pain.
- Acute kidney injury. Postmarketing reports in the setting of severe GI adverse reactions causing volume depletion. Stay well hydrated and contact us for persistent vomiting or diarrhea.
- Hypersensitivity reactions. Serious reactions including anaphylaxis and angioedema have been reported. Discontinue and seek emergency care for signs of a serious allergic reaction.
- Diabetic retinopathy complications in patients with type 2 diabetes. Monitor and have a baseline and periodic eye exam.
- Heart rate increase. A mean increase of 1 to 4 bpm has been observed; monitor in patients with tachyarrhythmia history.
- Suicidal behavior and ideation. Postmarketing signal under review; monitor mood and discontinue if new or worsening symptoms of depression or suicidal ideation develop.
- Hypoglycemia. Risk is elevated when Wegovy is co-administered with insulin or insulin secretagogues (sulfonylureas). Dose reduction of these agents may be needed.
Pregnancy and breastfeeding
Wegovy is not recommended during pregnancy. Animal studies showed adverse developmental outcomes. Because semaglutide has a long half-life (approximately one week) and full washout takes several weeks, Wegovy should be discontinued at least 2 months before a planned pregnancy. If an unplanned pregnancy occurs, stop Wegovy and contact us promptly. For breastfeeding, data are insufficient; discuss risks and benefits with your clinician before use.
Drug interactions
Wegovy slows gastric emptying and can affect the absorption of concomitantly administered oral medications. Use with caution in patients taking oral medications that require rapid gastrointestinal absorption or have a narrow therapeutic window. Inform us about every medication and supplement you take.
Wegovy® is a registered trademark of Novo Nordisk A/S. Midwest Mind & Body Healthcare is an independent clinical practice and is not affiliated with, endorsed by, or sponsored by Novo Nordisk. This page is provided for patient education and does not replace the FDA-approved Prescribing Information or Medication Guide. Last reviewed 2026-04-21.
Wegovy prescribing across 16 states.
In-person appointments are available at our Papillion, Nebraska office. Telehealth appointments are available for patients physically located in any of the states listed below. Labs are obtained locally at your preferred lab.
FAQ
Common questions about Wegovy.
Who qualifies for Wegovy?
Wegovy is FDA-approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. It is also FDA-approved to reduce the risk of major adverse cardiovascular events in adults with established CVD and overweight or obesity. Eligibility is confirmed during your initial evaluation.
Does insurance cover Wegovy?
Many commercial insurance plans cover Wegovy, typically with a prior authorization documenting BMI and weight-related conditions. Coverage for weight-management indications varies by plan and employer group. Medicare does not cover Wegovy for weight loss alone, though it may cover semaglutide for the cardiovascular risk-reduction indication. We prepare prior authorizations as part of the initial visit.
How much does Wegovy cost without insurance?
Retail cash pricing is approximately $1,000 per month without insurance. Novo Nordisk offers a savings program for eligible commercially insured patients, and NovoCare Pharmacy offers direct-to-patient cash pricing at a lower rate. Our clinic visit fees ($60 initial, $60 per refill) are separate from medication cost, which is billed by the pharmacy.
How long can I stay on Wegovy?
Wegovy is indicated for chronic weight management, meaning long-term use. Clinical trials have followed patients on semaglutide 2.4mg for more than two years with continued benefit. Obesity is a chronic relapsing condition, and current evidence suggests most patients need ongoing treatment to maintain results. If you hit a GLP-1 weight loss plateau, we evaluate nutrition, sleep, stress, and dose optimization before considering changes.
What happens when I stop Wegovy?
Most patients regain a significant portion of lost weight within a year of discontinuing Wegovy, because the medication addresses a chronic physiology. Cardiometabolic improvements (blood pressure, lipids, glucose) also tend to regress. We discuss long-term plans, tapering strategies, and realistic expectations at the start of treatment.
Can Wegovy be used with thyroid conditions?
Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Common thyroid conditions such as hypothyroidism (Hashimoto's) are not contraindications, though thyroid status should be optimized and monitored. We review your thyroid history at the initial evaluation.
Can I get Wegovy by telehealth in Nebraska?
Yes. Wegovy can be prescribed by telehealth for patients physically located in any of the 16 states we serve (NE, IA, KS, CO, AZ, IL, UT, ID, NM, KY, MT, ND, SD, VT, NH, ME). Labs and basic vitals are obtained locally. In-person visits are also available at our Papillion office.
Why not a subscription telehealth service?
Subscription services typically charge $200 to $400 per month as a recurring plan. Our model: a $60 initial consult and $60 per refill with a real clinician, so you can use your insurance for the FDA-approved medication and pay us only for clinical work. No subscription, no auto-renewal, no upsells.
Real clinic. Real prescribing. No subscription.
Wegovy prescribing from a dual ANCC board-certified nurse practitioner. $60 visit + medication. In-person in Papillion or telehealth in 16 states.
Book an Appointment